Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) COO Weiguo Ye sold 12,820 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the transaction, the chief operating officer directly owned 700,000 shares in the company, valued at $4,305,000. This trade represents a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Weiguo Ye also recently made the following trade(s):
- On Wednesday, May 20th, Weiguo Ye sold 9,400 shares of Gyre Therapeutics stock. The stock was sold at an average price of $6.15, for a total value of $57,810.00.
Gyre Therapeutics Stock Down 1.9%
Gyre Therapeutics stock traded down $0.12 during mid-day trading on Friday, hitting $6.06. The company had a trading volume of 86,973 shares, compared to its average volume of 90,296. The stock has a market cap of $588.00 million, a price-to-earnings ratio of -67.33 and a beta of 2.03. Gyre Therapeutics, Inc. has a 1 year low of $5.97 and a 1 year high of $11.61. The business has a fifty day moving average of $7.29 and a 200 day moving average of $7.61.
Analyst Ratings Changes
A number of analysts have weighed in on GYRE shares. Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Zacks Research lowered shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Finally, Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $17.00.
View Our Latest Report on GYRE
Hedge Funds Weigh In On Gyre Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Gyre Therapeutics by 9.5% during the 3rd quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after purchasing an additional 1,900 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Gyre Therapeutics by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock worth $301,000 after purchasing an additional 1,941 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares in the last quarter. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Featured Articles
- Five stocks we like better than Gyre Therapeutics
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
